Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breakthrough study could eliminate need for Blood-Cleansing procedure in rare blood disease

NCT ID NCT05468320

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

Summary

This study tested whether a combination of two medications could effectively treat a rare, serious blood disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP) without using the standard first treatment of therapeutic plasma exchange. The trial involved 51 adults with iTTP who received caplacizumab and immunosuppressive therapy. Researchers wanted to see if this drug combination alone could bring patients into remission without needing the plasma exchange procedure, which filters harmful antibodies from the blood.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Duke University Medical Center Site Number : 8400022

    Durham, North Carolina, 27710-4000, United States

  • Investigational Site Number : 0560003

    Yvoir, 5530, Belgium

  • Investigational Site Number : 1240001

    Toronto, Ontario, M5B 1W8, Canada

  • Investigational Site Number : 2030001

    Brno, 62500, Czechia

  • Investigational Site Number : 2030003

    Prague, 128 00, Czechia

  • Investigational Site Number : 2500001

    Paris, 75012, France

  • Investigational Site Number : 2500002

    Bois-Guillaume, 76230, France

  • Investigational Site Number : 2500003

    Paris, 75010, France

  • Investigational Site Number : 2500005

    Lille, 59037, France

  • Investigational Site Number : 2760001

    Frankfurt am Main, 60590, Germany

  • Investigational Site Number : 2760002

    Cologne, 50937, Germany

  • Investigational Site Number : 2760004

    Hanover, 30625, Germany

  • Investigational Site Number : 2760006

    Berlin, 10117, Germany

  • Investigational Site Number : 3800001

    Milan, Lombardy, 20122, Italy

  • Investigational Site Number : 3800003

    Avellino, Campania, 83100, Italy

  • Investigational Site Number : 3800004

    Vicenza, 36100, Italy

  • Investigational Site Number : 3800005

    Verona, 37134, Italy

  • Investigational Site Number : 3800006

    Genova, 16132, Italy

  • Investigational Site Number : 3920001

    Iruma-gun, Saitama, 350-0495, Japan

  • Investigational Site Number : 3920003

    Kurashiki-shi, Okayama-ken, 710-8602, Japan

  • Investigational Site Number : 5280002

    Amersfoort, 3818 TZ, Netherlands

  • Investigational Site Number : 7240001

    Madrid / Madrid, Madrid, Comunidad de, 28007, Spain

  • Investigational Site Number : 8260001

    London, London, City of, NW1 2PG, United Kingdom

  • Investigational Site Number : 8260002

    Liverpool, L7 8XP, United Kingdom

  • Johns Hopkins University- Site Number : 8400007

    Baltimore, Maryland, 21287, United States

  • The Ohio State University Comprehensive Cancer Center - Site Number : 8400001

    Columbus, Ohio, 43210, United States

  • University of Alabama- Site Number : 8400011

    Birmingham, Alabama, 35233, United States

Conditions

Explore the condition pages connected to this study.

THROMBOTIC THROMBOCYTOPENIC PURPURA